

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

SK-MES-1

RRID:CVCL_0630

Type: Cell Line

Proper Citation

RRID:CVCL_0630

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0630

Proper Citation: RRID:CVCL_0630

Description: Cell line SK-MES-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung squamous cell carcinoma

Defining Citation: [PMID:833871](#), [PMID:2990217](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:4005855](#), [PMID:6935474](#), [PMID:7017212](#), [PMID:7736387](#), [PMID:8385084](#), [PMID:11583962](#), [PMID:12794755](#), [PMID:14581340](#), [PMID:15746151](#), [PMID:16187286](#), [PMID:18083107](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22460905](#), [PMID:24002593](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-MES-1

Synonyms: SK MES 1, SKMES-1, SK-Mes-1, SK-MES1, SKMES1, SK-MES, SKMES

Cross References: BTO:BTO_0002203, CLO:CLO_0009033, CLO:CLO_0009048, CLO:CLO_0009049, EFO:EFO_0002334, CLDB:cl4325, CLDB:cl4326, CLDB:cl4329,

AddexBio:C0016029/4989, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-58, BioGRID_ORCS_Cell_line:464, BioSample:SAMN03473164, BioSample:SAMN10987781, cancercellines:CVCL_0630, CancerTools:161935, CCRID:1101HUM-PUMC000262, CCRID:3101HUMSCSP5010, CCRID:3101HUMTCHu110, CCRID:4201HUM-CCTCC00619, Cell_Model_Passport:SIDM01103, CGH-DB:191-1, CGH-DB:9180-4, ChEMBL-Cells:ChEMBL3307450, ChEMBL-Targets:ChEMBL614923, CLS:300339, Cosmic:687832, Cosmic:909728, Cosmic:933577, Cosmic:934464, Cosmic:1006538, Cosmic:1071896, Cosmic:1089225, Cosmic:1176620, Cosmic:1219089, Cosmic:1239912, Cosmic:1434962, Cosmic:1995637, Cosmic:2060529, Cosmic:2125289, Cosmic:2696402, Cosmic:2772162, Cosmic-CLP:909728, DepMap:ACH-000665, DSMZ:ACC-353, DSMZCellDive:ACC-353, ECACC:91091804, ECACC:93120837, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:909728, GEO:GSM62971, GEO:GSM206544, GEO:GSM274789, GEO:GSM274819, GEO:GSM513971, GEO:GSM514561, GEO:GSM784266, GEO:GSM827318, GEO:GSM887590, GEO:GSM888673, GEO:GSM1374881, GEO:GSM1670444, IARC_TP53:8201, IARC_TP53:18793, ICLC:HTL95004, IGRhCellID:SKMES1, IZSLER:BS TCL 72, KCB:KCB 200821YJ, KCLB:30058, LiGeA:CCLE_382, LINCS_HMS:50043, LINCS_LDP:LCL-1583, NCBI_Iran:C562, NCI-DTP:SK-MES-1, PharmacDB:SKMES1_1401_2019, PRIDE:PXD030304, Progenetix:CVCL_0630, PubChem_Cell_line:CVCL_0630, TOKU-E:3142, Ubigen:YC-C019, Wikidata:Q54954357

ID: CVCL_0630

Record Creation Time: 20220427T221547+0000

Record Last Update: 20260920T005753+0000

Ratings and Alerts

No rating or validation information has been found for SK-MES-1.

Warning: Discontinued: ECACC; 91091804

Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 556 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pan K, et al. (2026) Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy. *Biochemical pharmacology*, 243(Pt 2), 117562.

Gao Y, et al. (2026) AMT inhibits the progression of non-small cell lung cancer by suppressing the PI3K/AKT/GSK-3 β -catenin pathway via H3K27me3 regulation. *European journal of pharmacology*, 1011, 178460.

Leonardi L, et al. (2026) TLR7 induces autophagy in non-small cell lung cancer tumor cells and influences anti-tumors responses in patients. *Translational lung cancer research*, 15(4), 75.

Vendramin R, et al. (2026) Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome. *Immunity*, 59(5), 1398.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.

Yang T, et al. (2026) Covalent Inhibition of SHMT2 by Gambogic Acid Induces Ferroptosis Through Mitochondrial Collapse in Triple-Negative Breast Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(42), e20252.

Ma H, et al. (2025) Genetic susceptibility to lung squamous cell carcinoma: new insights on 9q33.2 variants and tobacco smoking. *Carcinogenesis*, 46(2).

Yuan L, et al. (2025) Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degradar of the Nuclear Pore Complex. *Cancer discovery*, 15(12), 2505.

Khatib TO, et al. (2025) TGF- β 1-mediated intercellular signaling fuels cooperative cellular invasion. *Cell reports*, 44(2), 115315.

Burger N, et al. (2025) The human zinc-binding cysteine proteome. *Cell*, 188(3), 832.

Specht C, et al. (2025) An engineered glutamic acid tRNA for efficient suppression of pathogenic nonsense mutations. *Nucleic acids research*, 53(12).

Suvilesh KN, et al. (2024) Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(17), 3855.

Torres-Martínez S, et al. (2024) Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma. *Molecular oncology*, 18(1), 190.

Ghezzi C, et al. (2023) Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3. *Scientific reports*, 13(1), 1442.

Kreus MA, et al. (2023) High NHLRC2 expression is associated with shortened survival in lung adenocarcinoma. *Translational lung cancer research*, 12(6), 1221.

Adorni MP, et al. (2023) A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC. International journal of molecular sciences, 24(2).

Prasad CB, et al. (2023) The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity. Research square.

Lei K, et al. (2023) Effects of Lipid Metabolism-Related Genes PTGIS and HRASLS on Phenotype, Prognosis, and Tumor Immunity in Lung Squamous Cell Carcinoma. Oxidative medicine and cellular longevity, 2023, 6811625.

Thuya WL, et al. (2023) FAM3C in circulating tumor-derived extracellular vesicles promotes non-small cell lung cancer growth in secondary sites. Theranostics, 13(2), 621.

Bodnar-Wachtel M, et al. (2023) Inflammasome-independent NLRP3 function enforces ATM activity in response to genotoxic stress. Life science alliance, 6(4).